https://www.selleckchem.com/pr....oducts/trimethoprim.
In the Informing the Pathway of COPD Treatment (IMPACT) trial, single-inhaler triple-therapy fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) reduced moderate/severe exacerbation rates vsFF/VI and UMEC/VI in patients with symptomatic COPD and a history of exacerbations, with a similar safety profile. Are trial outcomes with single-inhaler triple-therapy FF/UMEC/VI vs FF/VI and UMEC/VI affected by age in patients with symptomatic COPD and a history of exacerbations? IMPACT was a phase III, double-blind, 52-week tri
Like
Comment
Share
